Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

NCT00165399 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Prostate
Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: Estramustine
DRUG: Casodex
DRUG: Zoladex

Sponsor

Dana-Farber Cancer Institute